Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the sleep disorders (insomnia, narcolepsy, restless legs syndromes, and obstructive sleep apnea) drug market will reach $3.26 billion in 2008. According to the new DR Pipeline Report entitled Sleep Disorders Pipeline Analysis: Increased Competition to Awaken Market by 2008, Pfizer's efforts in the sleep disorders drug market will result in a 20-fold increase in its share of this market by 2008.

"Since its merger with Pharmacia, Pfizer has indicated a serious interest in the sleep disorders market," said Heather Martin, analyst at Decision Resources. "This interest is exemplified by a 2002 development and commercialization agreement with Neurocrine for the gamma-aminobutyric acid (GABA)/benzodiazepine agonist indiplon, which will be a major sleep disorders drug by 2008. A U.S. composition patent for indiplon was awarded in 2002, providing a long duration of patent exclusivity following its anticipated launch."

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. Geared toward business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

New Report From InterStudy Evaluates Implications of Anthem-WellPoint Merger For HMO Industry

View Now